AU2001261269A1 - 1,2,4-trisubstituted benzenes as inhibitors of 15-lipoxygenase - Google Patents
1,2,4-trisubstituted benzenes as inhibitors of 15-lipoxygenaseInfo
- Publication number
- AU2001261269A1 AU2001261269A1 AU2001261269A AU6126901A AU2001261269A1 AU 2001261269 A1 AU2001261269 A1 AU 2001261269A1 AU 2001261269 A AU2001261269 A AU 2001261269A AU 6126901 A AU6126901 A AU 6126901A AU 2001261269 A1 AU2001261269 A1 AU 2001261269A1
- Authority
- AU
- Australia
- Prior art keywords
- lipoxygenase
- inhibitors
- trisubstituted benzenes
- trisubstituted
- benzenes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21149800P | 2000-06-14 | 2000-06-14 | |
US60211498 | 2000-06-14 | ||
PCT/US2001/014795 WO2001096298A2 (en) | 2000-06-14 | 2001-05-08 | 1,2,4-trisubstituted benzenes as inhibitors of 15-lipoxygenase |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001261269A1 true AU2001261269A1 (en) | 2001-12-24 |
Family
ID=22787160
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001261269A Abandoned AU2001261269A1 (en) | 2000-06-14 | 2001-05-08 | 1,2,4-trisubstituted benzenes as inhibitors of 15-lipoxygenase |
Country Status (8)
Country | Link |
---|---|
US (1) | US6906094B2 (en) |
EP (1) | EP1294687A2 (en) |
JP (1) | JP2004503534A (en) |
AU (1) | AU2001261269A1 (en) |
BR (1) | BR0111383A (en) |
CA (1) | CA2411495A1 (en) |
MX (1) | MXPA02011750A (en) |
WO (1) | WO2001096298A2 (en) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1287789C (en) * | 2002-02-08 | 2006-12-06 | 霍夫曼-拉罗奇有限公司 | Methods of treating and preventing bone loss |
US20060019269A1 (en) * | 2002-10-17 | 2006-01-26 | Decode Genetics, Inc. | Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment |
US7851486B2 (en) * | 2002-10-17 | 2010-12-14 | Decode Genetics Ehf. | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment |
EP1579010A4 (en) * | 2002-10-17 | 2010-07-21 | Decode Genetics Ehf | Susceptibility gene for myocardial infarction; methods of treatment |
US20080293750A1 (en) * | 2002-10-17 | 2008-11-27 | Anna Helgadottir | Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment |
US7507531B2 (en) * | 2002-10-17 | 2009-03-24 | Decode Genetics Chf. | Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction |
US7144911B2 (en) | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
US7279576B2 (en) | 2002-12-31 | 2007-10-09 | Deciphera Pharmaceuticals, Llc | Anti-cancer medicaments |
US20050272051A1 (en) * | 2003-09-17 | 2005-12-08 | Decode Genetics Ehf. | Methods of preventing or treating recurrence of myocardial infarction |
US20100216863A1 (en) * | 2004-01-30 | 2010-08-26 | Decode Genetics Ehf. | Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment |
US8158362B2 (en) * | 2005-03-30 | 2012-04-17 | Decode Genetics Ehf. | Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype |
US20060252831A1 (en) * | 2005-05-06 | 2006-11-09 | Christopher Offen | Method for the treatment of magnesium and potassium deficiencies |
US20060252830A1 (en) * | 2005-05-06 | 2006-11-09 | Brandon Stephen F | Method for the treatment of magnesium and potassium deficiencies |
KR101810975B1 (en) * | 2010-07-08 | 2017-12-20 | 에스케이바이오팜 주식회사 | Pharmaceutical compositions comprising carbamoyloxy arylalkanoyl arylpiperazine compound |
WO2012154249A1 (en) * | 2011-02-17 | 2012-11-15 | Theravance, Inc. | Substituted aminobutyric derivatives as neprilysin inhibitors |
US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
MX2018009840A (en) * | 2016-02-16 | 2019-01-21 | Univ Queensland | Sulfonylureas and related compounds and use of same. |
SG11202007198WA (en) | 2018-01-31 | 2020-08-28 | Deciphera Pharmaceuticals Llc | Combination therapy for the treatment of gastrointestinal stromal tumors |
SG11202101480XA (en) * | 2018-08-15 | 2021-03-30 | Inflazome Ltd | Novel sulfonamideurea compounds |
BR112022002609A2 (en) | 2019-08-12 | 2022-08-09 | Deciphera Pharmaceuticals Llc | METHODS OF TREATMENT OF GASTROINTESTINAL STROMAL TUMORS |
WO2021030405A1 (en) | 2019-08-12 | 2021-02-18 | Deciphera Pharmaceuticals, Llc | Ripretinib for treating gastrointestinal stromal tumors |
KR20220123058A (en) | 2019-12-30 | 2022-09-05 | 데시페라 파마슈티칼스, 엘엘씨. | 1-(4-Bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl ) -3-Phenylurea composition |
DK4084778T3 (en) | 2019-12-30 | 2023-12-11 | Deciphera Pharmaceuticals Llc | AMORPHOUS KINASE INHIBITOR FORMULATIONS AND METHODS OF USING THEREOF |
US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU567140B2 (en) | 1984-01-06 | 1987-11-12 | Shionogi & Co., Ltd. | Sulphonamido-benzamide derivatives |
DE4238233A1 (en) * | 1992-11-12 | 1994-05-19 | Fahlberg List Pharma Gmbh | Inhibiting 5- or 15-lipoxygenase or cyclo:oxygenase - using N-sulphonyl-aminophenol derivs., e.g. for treating asthma, inflammation or allergy |
AU1529799A (en) | 1997-12-23 | 1999-07-12 | Warner-Lambert Company | Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis |
BR0111564A (en) * | 2000-06-14 | 2003-04-29 | Warner Lambert Co | Indole and benzimidazole as 15-lipoxygenase inhibitors |
-
2001
- 2001-05-08 CA CA002411495A patent/CA2411495A1/en not_active Abandoned
- 2001-05-08 US US10/362,104 patent/US6906094B2/en not_active Expired - Fee Related
- 2001-05-08 BR BR0111383-6A patent/BR0111383A/en not_active IP Right Cessation
- 2001-05-08 MX MXPA02011750A patent/MXPA02011750A/en active IP Right Grant
- 2001-05-08 JP JP2002510442A patent/JP2004503534A/en active Pending
- 2001-05-08 EP EP01935151A patent/EP1294687A2/en not_active Withdrawn
- 2001-05-08 AU AU2001261269A patent/AU2001261269A1/en not_active Abandoned
- 2001-05-08 WO PCT/US2001/014795 patent/WO2001096298A2/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
BR0111383A (en) | 2003-05-13 |
WO2001096298A3 (en) | 2002-06-27 |
WO2001096298A2 (en) | 2001-12-20 |
JP2004503534A (en) | 2004-02-05 |
US6906094B2 (en) | 2005-06-14 |
CA2411495A1 (en) | 2001-12-20 |
EP1294687A2 (en) | 2003-03-26 |
MXPA02011750A (en) | 2003-03-27 |
US20040053983A1 (en) | 2004-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001261269A1 (en) | 1,2,4-trisubstituted benzenes as inhibitors of 15-lipoxygenase | |
AU2001258771A1 (en) | -secretase inhibitors | |
AU2002219555A1 (en) | VLA-4 Inhibitors | |
AU4878601A (en) | Aromatic amide compounds | |
AU2001296961A1 (en) | 17-beta-hydroxysteroid dehydrogenase-ii inhibitors | |
HK1041407B (en) | Diarylbenzopyran derivatives as cyclooxygenase-2 inhibitors | |
AU2002211663A1 (en) | Nf-$g(k)b inhibitors | |
AU2001234088A1 (en) | TNF-alpha inhibitors | |
AU2002214163A1 (en) | Pyridyl-substituted triazoles as tgf inhibitors | |
AU5248800A (en) | Fading inhibitors | |
AU1530001A (en) | Inhibitor compositions | |
AU6381701A (en) | Bisamidino compounds as nhe-3 inhibitors | |
AU2001236052A1 (en) | Urease inhibitors | |
AU4037301A (en) | Microbial inhibitory compositions | |
AU2001259218A1 (en) | Substituted phenyl farnesyltransferase inhibitors | |
AU7961300A (en) | Kainic acid neurocytotoxicity inhibitors | |
IL148275A0 (en) | Substituted 3-phenyl-5-alkoxy-1, 3, 4-oxdiazol-2-ones- and their use as lipase inhibitors | |
AU3235100A (en) | Prothease inhibitors | |
AU3761400A (en) | Amino-thio-acrylonitriles as mek inhibitors | |
AU2001232245A1 (en) | Tnf- alpha inhibitors | |
AU2002224550A1 (en) | Corrosion inhibitors | |
AU2002214038A1 (en) | Inhibitors of transglutaminases | |
AU5179800A (en) | Mycolactone and related compounds, compositions and methods of use | |
AU2002224835A1 (en) | Dihydroisoquinolines as novel phosphodiesterase inhibitors | |
AU2000280045A1 (en) | Acetaminophen/non-steroidal anti-inflamatory drug-glucosamine composition |